Wegovy and Pharmac: where public funding actually stands

The short version: Wegovy (semaglutide) is approved by Medsafe for weight management and has been recommended for public funding by Pharmac's own advisory group — but it is not funded, and Pharmac has said plainly that it "cannot say when, or if, any medicine will be funded." Those three facts describe three different steps, and New Zealand coverage routinely blurs them.

The three steps, untangled

Medsafe approval means the regulator has assessed a medicine as safe and effective enough to be sold here. Wegovy and Mounjaro (tirzepatide) both have it for weight management. Approval says nothing about who pays — both are private-pay today (our guide to GLP-1 medicines in New Zealand has the current prices and the full list of what is approved).

An advisory recommendation is a step inside Pharmac. Its Obesity Treatment Advisory Group considered a Wegovy funding application in December 2025 and recommended funding for chronic weight management, rating it a high priority for people with high BMI and related conditions. The group also said funding rules would be needed — in practice Pharmac's Special Authority system, where a prescriber applies for funding patient by patient.

The Options for Investment list is where Wegovy now sits: assessed, prioritised, and waiting against everything else on the list for budget. Being on the list is genuine progress — most applications never get there — but it is not a commitment, and medicines can sit on it for years.

What about Mounjaro?

Pharmac has received no application to fund Mounjaro for weight management at all. The application it holds is for insufficiently controlled type 2 diabetes, which it is assessing separately. For weight management, Mounjaro is further from public funding than Wegovy, not closer.

What this means for New Zealand

Today, every GLP-1 medicine used for weight management in New Zealand is private-pay, and nothing announced changes that. If Pharmac does fund Wegovy, expect Special Authority criteria — funding targeted by BMI and related conditions, not open access. The older GLP-1s Trulicity (dulaglutide) and Victoza (liraglutide) remain funded only for type 2 diabetes under existing criteria. Anyone currently paying privately should not change any plan on the strength of a list placement; the honest reading of Pharmac's own words is that a decision has no public timeline.

What we still don't know

When — or whether — Options for Investment becomes a funded listing; what the Special Authority criteria would be; and whether the separate application for Wegovy in people with heart conditions moves first. We'll report each of those steps when Pharmac announces them.